Neurofit announced on the 13th that it will participate in the '2025 BIO International Convention (hereinafter BIO USA)' held in Boston, USA from the 16th to the 19th.
At this event, Neurophyt will present 'Neurophet AQUA AD', a software that enables dementia treatment prescriptions, treatment effects, and side effects monitoring. The solution quantitatively analyzes MRI (magnetic resonance imaging) and PET (positron emission tomography) images, providing a precise brain image analysis function for the entire administration of Alzheimer's disease anti-amyloid antibody treatment.
Recently, as interest in clinical trials for Alzheimer's disease treatment has increased in the pharmaceutical and biotechnology industry, the importance of quantitative brain imaging biomarker analysis has also been emphasized. In particular, global demand for Neurofit Aqua AD is increasing, as monitoring of side effects of treatments such as lecanemab and donanemab is essential.
Neurophy will set up a booth at the Korea Pavilion, which is jointly operated by the Korea Biotechnology Industry Organization and the Korea Trade-Investment Promotion Agency (KOTRA), to introduce the following products: Neurophyt Aqua AD, brain nerve degeneration image analysis software Neurophyt Aqua, PET image quantitative analysis software Neurophyt SCALE PET, brain electrical stimulation image treatment planning software Neurophyt tES LAB, and transcranial electrical stimulation (tES) device Neurophyt innk.
Additionally, during this event, Neurofit plans to hold business meetings to strengthen its imaging CRO (clinical trial organization) business that can be utilized in clinical development of Alzheimer's disease treatment, and to build partnerships with global pharmaceutical companies and potential customers.
Neurofit Co-CEO Bin Jun-gil said, “Neurofit Aqua AD is receiving a lot of attention from domestic and foreign companies in the field of brain imaging-based biomarker development cooperation,” and “We will accelerate the development of our imaging CRO business through our participation in Bio USA and pursue business expansion into the companion diagnostics field in the future.”
- See more related articles
You must be logged in to post a comment.